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Abstract
Background: The clinical application of IFN-c release assays (IGRAs) has recently improved the diagnosis of latent
tuberculosis infection. In a multicenter study of the Tuberculosis Network European Trialsgroup (TBNET) we aimed to
ascertain in routine clinical practice the accuracy of a novel assay using selected peptides encoded in the mycobacterial
genomic region of difference (RD) 1 for the diagnosis of active tuberculosis in comparison with tuberculin skin test (TST),
QuantiFERON-TB GOLD In-Tube (Cellestis Ltd., Carnegie, Australia) and T-SPOT.TB (Oxfordimmunotec, Abingdon, UK).
Principal Findings: 425 individuals from 6 different European centres were prospectively enrolled. We found that sensitivity of
the novel test,TST, QuantiFERON-TBGOLD In-TubeandT-SPOT.TB wasrespectively 73.1%,85.3%,78.1%,and 85.2%;specificity
was respectively 70.6%, 48.0%, 61.9% and 44.3%; positive likelihoodratios were respectively 2.48, 1.64, 2.05, and 1.53; negative
likelihoodratioswererespectively 0.38,0.31,0.35,0.33.SensitivityofTSTcombinedwiththe noveltest,QuantiFERON-TBGOLD
In-Tube and T-SPOT.TB increased up to 92.4%, 97.7% and 97.1%, respectively. The likelihood ratios of combined negative
results of TST with, respectively, the novel test, QuantiFERON-TB GOLD In-Tube and T-SPOT.TB were 0.19, 0.07 and 0.10.
Conclusions: The assay based on RD1 selected peptides has similar accuracy for active tuberculosis compared with TST and
commercial IGRAs. Then, independently of the spectrum of antigens used in the assays to elicit mycobacterial specific
immune responses, the novel test, IGRAs, and the TST do not allow an accurate identification of active tuberculosis in clinical
practice. However, the combined use of the novel assay or commercial IGRAs with TST may allow exclusion of tuberculosis.
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Introduction
Tuberculosis control is based on the consequent use of
preventive chemotherapy in individuals with latent tuberculosis
infection (LTBI) who are at risk of developing active disease and
on the rapid diagnosis and effective treatment of infectious cases
[1–3]. While the identification of patients with active tuberculosis
can rapidly be established by the detection of alcohol acid fast
bacilli (AFB) on sputum smears, early diagnosis of infectious cases
by sputum microscopy is only possible in approximately 50% of
cases [4]. The sub-optimal performances of existing diagnostic
tools [4], in terms of both speed and sensitivity, delayed diagnosis
and, consequently, treatment of active tuberculosis.
The recent introduction of T-cell-based interferon (IFN)-c
release assays (IGRAs), using antigens belonging to M. tuberculosis
region of difference (RD) 1 (including early secreted antigenic
target [ESAT]-6 and culture filtrate protein 10 [CFP]-10)
represents a significant step towards improved LTBI diagnosis
[5–9]. There is growing evidence that in low incidence settings
both the commercial IGRAs currently available, the Quantiferon-
GOLD In-tube assay (Cellestis Ltd., Carnegie, Australia) and the
T-SPOT.TB assay (Oxfordimmunotec, Abingdon, UK) are less
affected by bacillus Calmette-Guerin (BCG) vaccination than the
tuberculin skin test (TST) and that they are more specific and
correlate better with exposure to an infected index case [10–13].
Although these commercial assays provide an accurate diagnosis of
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cannot discriminate between active tuberculosis and LTBI. Thus,
further clinical workup is required to rule out active tuberculosis
after a positive response to these tests.
Recently the design of a novel in vitro immune diagnostic
enzyme-linked immunospot (ELISPOT) and whole blood ELISA
(WBE) for IFN-c using multiepitopic peptides that are selected by
computational analysis from CFP-10 and ESAT-6 as stimulating
antigens has been reported [14]. It has been shown that the
response to RD1 selected peptides can be detected in subjects with
ongoing M. tuberculosis replication, such as during active tubercu-
losis and/or recent infection [15–17]. This response is mediated by
CD4
+ T effector cells, shown to undergo clonal expansion during
M. tuberculosis replication, followed by a contraction phase after
efficacious therapy culminating in the generation of CD4
+
memory T-cells [18,19]. These studies were conducted at one
center in Italy, a country with a low tuberculosis incidence of
,10/100.000 [20]. The aims of this multicenter study were: i) to
evaluate whether this assay based on RD1 selected peptides may
help in providing evidence of active tuberculosis; ii) to compare the
response to this novel assay with TST and the commercially
available RD1 tests, individually and in combination for the
diagnostic work-up of active tuberculosis [21].
Materials and Methods
Study design
Following obtaining of informed consent, patients with a clinical
suspicion of tuberculosis (abnormal chest radiograph suggestive of
tuberculosis and/or other signs and symptoms such as persistent
cough, haemoptysis, weight loss, fever) were prospectively
recruited at participating centers of the Tuberculosis Network
European Trialsgroup (TBNET): Bulgaria (Department of Immu-
nology and Allergology, National Center for Infectious and
Parassitic Diseases, Sofia), Germany (Medical Clinic, Research
Centre Borstel, Borstel), Italy (INMI and University La Sapienza,
Rome; Scientific Institute San Raffaele, Milan) and Spain
(Hospital Universitari Germans Trias i Pujol; Barcelona) between
November 2005 and March 2008.
Patients underwent clinical and microbiological examinations
including chest radiographs to confirm or exclude the diagnosis of
tuberculosis. Briefly, 3 sequential respiratory expectorated or 2
induced sputum smears over the first 7 days following clinical
evaluation were collected. AFB smear and culture (on both,
Lowenstein-Jensen and Bactec MGIT, BD Biosciences Division,
Sparks, Maryland, USA) were performed on each specimen.
Additionally M. tuberculosis-specific RNA amplification was per-
formed on specimens from patients with a high likelihood for
tuberculosis in which examinations for AFB were negative [(Gen-
ProbeH Amplified
TM Mycobacterium Tuberculosis Direct (MTD)
Test, San Diego, CA, USA)]. TSTs were administered by the
Mantoux method with bioequivalent 5 Tuberculin Units (Biocine,
Chiron, Siena, Italy) or 2 Tuberculin Units (RT23, Statens Serum
Institute, Copenhagen, Denmark) [22,23] or 5 Units of PPD
Tuberculin Mammalian (BulBio-NCIPD, Sofia, Bulgaria). Indu-
rations were measured 48–72 hours following tuberculin admin-
istration by the ballpoint technique. Individuals with an induration
$10 mm [24] or in Bulgaria $15 mm [25–26] for those with past
BCG vaccination were classified as TST-positive [22].
For extra-pulmonary tuberculosis, M. tuberculosis-specific RNA
amplification (MTD Test) and/or nucleic acid amplification test
(NAT) for M. tuberculosis-specific DNA based on a commercial test
(BD ProbeTec ET system; BD Diagnostic Systems, Sparks, MD)
or based on a homemade version developed from the literature
[27] was performed on biopsy specimens and/or biological fluids;
moreover histology and AFB staining were performed on biopsies.
Enrolled patients were classified as ‘‘confirmed tuberculosis’’ if
the diagnosis was based: i) in those with pulmonary tuberculosis by
a positive culture for M. tuberculosis; ii) in those with extra-
pulmonary tuberculosis by a) positive M. tuberculosis-specific RNA
amplification and/or M. tuberculosis-specific NAT from biological
specimens or b) by histological pathological finding consistent with
tuberculosis and presence of AFB in a tissue sample or c) by
positive culture for M. tuberculosis in clinical samples (pleural fluid
and abscesses). Conversely, patients were classified as ‘‘clinical
tuberculosis’’ if the diagnosis was based on clinical and radiologic
criteria (having excluded other disease) including appropriate
response to anti-tuberculosis therapy.
We defined patients without tuberculosis as those admitted with
a suspicion of active tuberculosis, who subsequently showed
negative sputum for AFB smear and culture for M. tuberculosis with
either a resolution of clinical symptoms and radiographic
abnormalities after an antibiotic therapy not involving M.
tuberculosis active drugs, or presenting a confirmed alternative
diagnosis (e.g.: lung cancer).
Following admission, a 10–20 ml (depending on the center)
heparin venous blood sample was drawn from all enrolled
individuals. ELISPOT or WBE based on RD1 selected peptides
was performed. In a subgroup of patients the test was done in
parallel with the commercially available immune assays for
tuberculosis. Clinicians were blinded to the results of in vitro assays
and laboratory personnel were blinded to the status of the patient.
The study was approved by the ethics committee at all the
institutions in which the study was performed.
RD1 selected peptides and stimuli used for cell cultures
The selection of Human Leukocytes Antigens (HLA)-class II
restricted epitopes of ESAT-6 and CFP-10 M. tuberculosis proteins
was performed by quantitative implemented HLA peptide-binding
motifsanalysis as previously described for ESAT-6[14,15]. Peptides
were synthesized as free amino acid termini using Fmoc chemistry
(ABI, Bergamo, Italy). Lyophilized peptides were diluted in DMSO
at stock concentrations of 10 mg/mL for each peptide and stored at
280uC. RD1 selected peptides were used as follows: a pool of the
two ESAT-6 peptides (at 10 mg/mL each), a pool of the three CFP-
10 peptides (at2 mg/mL each). DMSOwasused as negative control
at 10 mg/mL. As positive control we used Phytohemagglutinin
(PHA) (Sigma, St Louis, MO, USA) at 5 mg/mL. RD1 selected
peptides from the same batch were provided to the all centerswith a
detailed protocol. Four out of the 5 external centers received
personal training from INMIs’ laboratory personnel for at least 2-
days. Inter-site communication was present all over the perfor-
mance of the study to solve any potential problem.
ELISPOT. 2.5610
5 peripheral blood mononuclear cells
(PBMC) were separated, washed twice and plated in the T-
SPOT.TB plates stimulated with or without RD1 selected peptides
and PHA, as described above and previously [14,15]. Cell cultures
were incubated overnight at 37uC, with 5% CO2. On the next
morning, the cells were washed off, and the ELISPOT was
developed following the manufacturer’s instructions (Oxford
Immunotec, UK). Spots were then counted by an automated
ELISA-Spot assay video analysis system (AELVIS, Hannover,
Germany). Evaluated spots had a size .15 U (1 U=50 mm2).
Indeterminate results were defined by values in the PHA-
stimulated samples below 34 spot-forming cells per million
PBMC. The RD1 selected peptide responses were scored as
positive if above 34 spot-forming cells/million PBMC. This cutoff
value was determined by constructing a receiver operator
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obtain the absolute value, the number of spot-forming cells in the
negative controls was subtracted from the number of spot-forming
cells in the stimulated cultures. Clinicians were blinded to the
laboratory test results and laboratory personnel were blinded to
the status of the patients.
WBE. Briefly, aliquots of 0.5 ml per well of heparinized blood
were seeded in a 48-well plate and stimulated with or without RD1
selected peptides and PHA, as described above. Samples were then
incubated for 24 hours at 37uC in presence of 5% CO2 when an
amount of 100 ml of plasma was harvested. IFN-c levels in culture
supernatants were assessed by a commercially available kit
(QuantiFERON-CMI kit, Cellestis). For the results scoring, a
cut-off value of 0.7 IU/mL was chosen for all stimuli by
constructing a ROC curve. Indeterminate results were defined
by values in the PHA-stimulated samples below 0.7 IU/mL.
Commercially available assays
T-SPOT.TB and QuantiFERON-TB GOLD In-Tube assays
were performed and their results were scored as indicated by the
manufacturers.
Statistical Analysis. The tests performance was evaluated by
using categories of confirmed tuberculosis, clinical tuberculosis,
and no active tuberculosis. Cases with indeterminate responses to
in vitro assays were not included in the analysis. Sensitivity,
specificity and likelihood ratios with their 95% Confidence
Interval (CI), were computed for each test overall and according
to the diagnostic categories and tuberculosis localization.
Proportions were compared by using Fisher exact test and, for
paired data, McNemar chi-square test. Sensitivities of 2 tests used
in combination were obtained assuming that a positive result is
given by a positive response to at least one assay.
Furthermore the accuracy of two tests used in combination was
analyzed by computing the likelihood ratios, together with the
distribution of subjects with and without active tuberculosis,
according to the responses to the tests. Sensitivities and specificities
of diagnostic tests were compared by using a logistic regression
model with robust standard errors to account for the correlation
between observations. Two-tailed P values are reported.
Results
We consecutively enrolled 425 consenting adult patients from 6
different centres in Europe. Complete data were unavailable from
1 patient. Results from 11 (2.5%) subjects were found to be
indeterminate by in vitro assays based on RD1 selected peptides
and/or QuantiFERON-TB GOLD In-Tube (Figure 1). Among
them, 4 had active tuberculosis and 7 were without active
tuberculosis. These patients were similar to those without
indeterminate results in terms of age, sex, ethnicity, immune
suppressive therapy intake and presence of comorbidity conditions
(data not shown).
Figure 1. Study flow diagram. Abbreviations: TB: tuberculosis; RD: Region of Difference; Indeterm: indeterminate; TST: tuberculin skin test; QF:
QuantiFERON-TB GOLD In-Tube.
doi:10.1371/journal.pone.0003417.g001
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samples with valid in vitro test results. Demographic characteristics
of these subjects are shown in Table 1. Among them we classified
173 patients (41.9%) as having confirmed tuberculosis and 43
(10.4%) as having clinical tuberculosis. We excluded active
tuberculosis in 197 patients (47.7%). Based on localization site,
146 (67.6%) were classified as having pulmonary tuberculosis, 56
(25.9%) extrapulmonary tuberculosis and 14 (6.5%) had both
pulmonary and extrapulmonary localization (Table 2).
Response to RD1 selected peptides assay and
comparison with the other tests
WBE and ELISPOT readouts significantly correlate for
the detection of the responses to RD1 selected
peptides. Evaluation of the response to RD1 selected peptides
was performed by 2 different readouts, the ELISPOT and the
WBE that we previously demonstrated to significantly correlate
with each other [15]. Also in this study, 138 samples were run in
parallel with a significant correlation (percentage of agreement:
80.4%; p=0.0001). Moreover no differences were found in terms
of detection of positive results in those with active tuberculosis
among the patients from the different centers (p.0.5). Given the
concordance of the results, the data were pooled together and
analyzed as a whole.
Response to immunological tests for tuberculosis: assay
based on RD1 selected peptides, TST, commercial IGRAs
For confirmed and clinical tuberculosis cases, diagnostic test
sensitivities were 73.1% (95% CI, 66.7–78.9%) with RD1 selected
peptides test, 85.3% (95%CI, 79.2–90.2%) with TST, 78.1% (95%
CI, 70.7–84.3%) with QuantiFERON-TB GOLD In-Tube, and
85.2% (CI, 76.1–91.9%) with T-SPOT.TB (Table 2).
To investigate whether inclusion of patients with clinical
tuberculosis in the analysis affected performance estimates, we
re-estimated sensitivity by using only confirmed cases. Sensitivity
remained stable and was 73.4% (CI, 66.2–79.8) with RD1 selected
peptides test, 83.8% (CI, 76.5–89.6) with TST, 81.8% (CI, 73.8–
88.2%) with QuantiFERON-TB GOLD In-Tube, and 89.9%
(CI,80.2–95.8%) with T-SPOT.TB (Table 2). No differences were
found between the results obtained considering confirmed
tuberculosis vs. clinical tuberculosis cases with the exception of
T-SPOT.TB for which a higher proportion of positive results was
observed for confirmed tuberculosis (62/69) vs. clinical tubercu-
losis (13/19, p=0.03). Results of immune responses were therefore
evaluated for patients with confirmed and clinical tuberculosis
pooled together, unless differently specified, and were defined as
patients with active tuberculosis.
Among patients with active tuberculosis, the RD1 selected
peptides assay was less sensitive than TST (in the 170 patients with
Table 1. Demographic and clinical characteristics of the subjects enrolled in the study.
Confirmed TB Clinical TB No Active TB Total
N. 173 (%) N. 43 (%) N. 197 (%) N. 413 (%)
Age years (median) 34 36 48 40
Gender
Female 69 (39.9) 15 (34.9) 67 (34.0) 151 (36.6)
Male 104 (60.1) 28 (65.1) 130 (66.0) 262 (63.4)
BCG
Yes 105 (60.6) 7 (16.2) 54 (27.4) 166 (46.0)
No 54 (31.2) 34 (79.0) 107 (54.3) 195 (54.0)
Unknown 14 (8.0) 2 (0.04) 36 (18.2) 52 (12.5)
Origin
Africa 29 (16.8) 6 (14.0) 11 (5.6) 46 (11.1)
Asia 17 (9.8) 10 (23.3) 9 (4.6) 36 8.7)
Eastern Europe 66 (38.2 5 (11.6) 31 (15.7) 102 (24.7)
South America 17 (9.8) 0 10 (5.1) 27 (6.5)
Western Europe 44 (25.4) 22 (51.2) 136 (69.0) 202 (48.9)
Past TB
Yes 0 0 27 (13.7) 27 (6.5)
No 173 (100) 43 (100) 170 (86.3) 386 (93.5)
Immune suppressive therapy
Yes 4 (2.3) 2 (4.7) 4 (2.0) 10 (2.4)
No 169 (97.7) 41 (95.3) 193 (98.0) 403 (97.6)
HIV status
Yes 3 (1.7) 0 4 (2.0) 7 (1.7)
No 155 (89.5) 43 (100) 167 (84.7) 365 (88.3)
Unknown 15 (8.6) 0 26 (13.2) 41 (9.9)
Abbreviations:
TB: tuberculosis; BCG: Bacillus Calmette and Guerin; HIV: Human Immunodeficiency Virus.
doi:10.1371/journal.pone.0003417.t001
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patients with results from both tests) (p=0.008), but not the
QuantiFERON-TB GOLD In-Tube (in the 154 patients with
results from both tests) (p=0.16).
We also evaluated the sensitivities of the different tests based on
tuberculosis localization. In Table 2, sensitivities for pulmonary,
extra-pulmonary and disseminated tuberculosis (pulmonary and
extra-pulmonary tuberculosis) are shown. Considering each test
per se, no significant difference in proportion of positive results was
observed in patients with active tuberculosis according to
tuberculosis localization [with the exception of TST for which
the highest proportion of positive results was recorded among
patients with pulmonary tuberculosis (p=0.027)].
Of the 132 patients with culture confirmed pulmonary
tuberculosis, 28 had a negative sputum smear. Among these
patients, sensitivity results were 64.3% (18/28; CI, 44.1–81.4) for
RD1 selected peptides test, 84.6% (22/26; CI, 65.1–95.6) for TST,
88.0% (22/25; CI, 68.8–97.5) for QuantiFERON-TB GOLD In-
Tube, and 83.3% (5/6; CI, 35.9–99.6) for T-SPOT.TB.
Compared to RD1 selected peptides test, the sensitivity for active
tuberculosis was significantly higher only for QuantiFERON-TB
GOLD In-Tube (p=0.037). M. tuberculosis-specific RNA amplifi-
cation was performed in 22 of these 27 subjects (8 sputa and 16
broncholavage) and resulted positive in 75% of sputa (6/8; CI,
34.9–96.8) and in 93.8% of broncholavages (15/16; CI, 69.8–99.8)
with an overall sensitivity of 86.4% (19/22; CI, 65.1–97.1). Among
the 118 patients with smear positive culture confirmed pulmonary
tuberculosis the sensitivity results were 77.1% (91/118; CI, 68.5–
84.3) by RD1 selected peptides test, 87.6% (78/89; CI, 79.0–93.7)
by TST, 80.5% (66/82; CI, 70.3–88.4) by QuantiFERON-TB
GOLD In-Tube, and 88.0% (44/50; CI, 75.7–95.5) by T-
SPOT.TB. No statistical difference was found between the single
tests’ results obtained in those smear positive vs those smear
negative.
Specificity for active tuberculosis was 70.6% (CI, 63.7–76.8%)
with RD1 selected peptides test, 48.0% (CI, 39.8–56.3%) with
TST, 61.9% (CI, 51.4–71.5%) with QuantiFERON-TB GOLD
In-Tube, and 44.3% (CI, 34.2–54.8%) with T-SPOT.TB (Table 2).
The specificity for active tuberculosis was significantly higher for
the assay based on RD1 selected peptides compared with TST
(p,0.001) and T-SPOT.TB (p,0.001).
Then we assessed whether the pair-wise combination of the tests
could lead to a better evaluation of active tuberculosis diagnosis and
we calculated the probabilities for the potential outcomes (double
positive, double negative and discordant results) given the disease
status.
Table 2. Accuracy for the diagnosis of active tuberculosis.
Sensitivity*
RD1 selected
peptides test TST
QuantiFERON-TB
GOLD In-Tube T-SPOT.TB
Positive over total (%) [CI]
According to diagnostic
criteria
Confirmed TB 127/173 (73.4) 114/136 (83.8) 99/121 (81.8) 62/69 (89.9)
[66.2–79.8] [76.5–89.6] [73.8–88.2] [80.2–95.8]
Clinical TB 31/43 (72.1) 37/41 (90.2) 22/34 (64.7) 13/19 (68.4)
[56.3–84.7] [76.9–97.3] [46.5–80.3] [43.4–87.4]
According to TB
localization
Pulmonary 109/146 (74.7) 100/115 (87.0) 88/107 (82.2) 49/56 (87.5)
[66.8–81.5] [79.4–92.5] [73.7–89.0] [75.9–94.8]
Extra-pulmonary 40/56 (71.4) 41/47 (89.4) 26/39 (66.7) 17/23 (73.9)
[57.8–82.7] [76.9–96.5] [49.8–80.9] [51.6–89.8]
Pulmonary and extra-
pulmonary
9/14 (64.3) 9/15 (60.0) 7/9 (77.8) 9/9 (100)
[35.1–87.2] [32.3–83.7] [40.0–97.2] [71.7–100.0]
Total 158/216 (73.1) 151/177 (85.3) 121/155 (78.1) 75/88 (85.2)
[66.7–78.9] [79.2–90.2] [70.7–84.3] [76.1–91.9]
Specificity**
139/197 (70.6) 72/150 (48.0) 60/97 (61.9) 43/97 (44.3)
[63.7–76.8] [39.8–56.3] [51.4–71.5] [34.2–54.8]
Positive likelihood ratio***
2.48 1.64 2.05 1.53
[1.97–3.1] [1.39–1.94] [1.57–2.67] [1.26–1.87]
Negative likelihood ratio***
0.38 0.31 0.35 0.33
[0.30–0.48] [0.21–0.45] [0.25–0.50] [0.19–0.58]
*evaluated on the total number of positive results over the total number of patients with active tuberculosis disease.
**evaluated on the total number of negative results over the total number of patients without active tuberculosis disease.
***evaluated on the total number of tuberculosis cases (confirmed and clinical tuberculosis).
Abbreviations:
TB: tuberculosis; RD: region of difference; TST: tuberculin skin test; CI: confidence interval.
doi:10.1371/journal.pone.0003417.t002
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considered was higher than sensitivities of each test (Table 3). In
particular the assay based on RD1 selected peptides combined
with TST led to a sensitivity of 92.4% (CI, 87.3–96.0%), with
QuantiFERON-TB GOLD In-Tube of 85.7% (CI, 79.2–90.8%),
and with T-SPOT.TB of 88.6% (CI, 80.1–94.4%) (Table 3). To
note that the highest sensitivities were obtained by using the
combination of TST with either QuantiFERON-TB GOLD In-
Tube [sensitivity of 97.7% (CI, 93.0–99.5%)], or T-SPOT.TB
[sensitivity of 97.1% (CI, 89.9–94.4%) (Table 3)]. Then we
estimated the likelihood ratios for the combination of the tests.
Positive results from both tests provided likelihood ratios of 2.92
for the RD1 selected peptides test combined with TST [CI, 2.15–
3.98], 3.21 with QuantiFERON-TB GOLD In-tube, [CI, 2.11–
4.89], and 2.20 with T-SPOT.TB [CI, 1.59–3.07], (Table 4).
Negative results on combined tests were associated with lower
negative likelihood ratios compared to that obtained by single
assay especially when a blood test was associated with TST. In
particular the negative likelihood ratio of the combination of RD1
selected peptides test with TST was 0.19 (CI, 0.11–0.33), with
QuantiFERON-TB GOLD In-Tube was 0.25 (CI, 0.16–0.38) and
with T-SPOT.TB was 0.27 (CI, 0.14–0.50) (Table 4). To note that
better negative likelihood ratios were obtained by the combination
of commercial tests with TST (Table 4).
Discussion
We present the results of a prospective multicenter trial of the
TBNET that was designed to investigate the performance of a
novel blood test based on RD1 selected peptides for the
immunodiagnosis of active tuberculosis.
The novel assay had a higher specificity for active tuberculosis
than the TST and commercial IGRAs, but it had a lower
sensitivity. Although the novel assay had a higher likelihood ratio,
none of the tests evaluated was accurate enough to discriminate
patients with active tuberculosis from those without, probably
because of the high levels of LTBI in the population studied.
Combined use of TST with either the RD1 selected peptides test
or with the other commercial IGRAs improved the diagnostic
accuracy for active disease, especially when considering the
combination of negative results, contributing to rapid exclusion
of tuberculosis. However, M. tuberculosis culture remains the
diagnostic gold standard for active tuberculosis and is required
for identifying drug resistance. Consequently, active tuberculosis
should not be ruled out in a high-risk individual without a
thorough microbiological work-up for tuberculosis disease.
The specificity of the assay based on RD1 selected peptides was
lower in this multicenter trial compared with earlier, smaller studies
of more limited patient groups [15,16]. Nevertheless, also in the
present study the test based on RD1 selected peptides maintains the
higher specificity compared to commercial IGRAs and TST which
is not unexpected. In fact, the commercial IGRAs and TST use a
greater variety of epitopes to elicit M. tuberculosis immune responses
by effector memory T-cells [28–29] being TST a crude preparation
of several mycobacterial antigens, and commercially IGRAs based
on pools of overlapping peptides spanning the whole length of CFP-
10 and ESAT-6 proteins [5]. Conversely the selective approach of
the design of the test based on RD1 selected peptides reduces false
positive test results at the cost of a loss of diagnostic sensitivity [14–
16]. Which would be more acceptable between false positive test
results that may lead to overtreatment or false negative test results
that potentially lead to missing of cases withactive tuberculosis to be
treated, is a matter of debate and is largely dependent upon the
prevalence of M. tuberculosis infection and the pre-test probability of
tuberculosis in a community.
Specificity of commercial IGRAs is considerably lower in the
present study compared to what was reported in a recent updated
meta-analysis [30]. This may be due to the fact that this report
involve the enrollment of patients with a suspicion of active
tuberculosis that could by affected also by LTBI, while the
literature reported in the meta-analyses [30] enclosed low-risk
subjects with no known tuberculosis exposure in low incidence
settings. Conversely sensitivity results were similar to those recently
reported in the literature because based on patients with active
disease [5,16,30].
Intermsofparametersusedtoevaluatetheaccuracyofdiagnostic
tests it is important to consider that while sensitivity and specificity
are easy and straightforward measures, they are limited and mustbe
considered as surrogates for patient-important outcomes. There is
still lack of adequate data on important outcomes such as accuracy
of diagnostic algorithms (rather than single tests), incremental or
added value of IGRAs, impact of IGRAs on clinical decision-
making and therapeutic choices, and the prognostic ability of
IGRAs to accurately identify individuals with LTBI who are at the
highest risk for progressing to active tuberculosis and therefore are
most likely to benefit from preventive therapy. These issues need to
be evaluated for further studies.
New tools for a rapid diagnosis of active tuberculosis are needed
especially for the smear negative and extra-pulmonary cases. In
the smear negative tuberculosis group, the overall response to
RD1 selected peptides was 64.3% and, among the tests used for
comparison, a significantly higher sensitivity was found only for
the QuantiFERON-TB GOLD In-Tube. Conversely the sensitiv-
ity for extra-pulmonary tuberculosis was 71.4% for the RD1
selected peptides and this value did not significantly differ from the
results obtained by the other tests, with the exception of TST.
However, in general, the size of these sub-groups of patients was
small and no definitive conclusion can be drawn.
The rate of indeterminate results in our study was similar to the
3% to 4% rates observed in other studies [31–33]. Moreover, the
Table 3. Estimates of sensitivities for the combination of the diagnostic tests studied.
Combined tests % [CI]
TST QuantiFERON-TB GOLD In-Tube T-SPOT.TB
RD1 selected peptides test 92.4 [87.3–96.0] 85.7 [79.2–90.8] 88.6 [80.1–94.4]
TST - 97.7 [93.0–99.5] 97.1 [89.9–99.6]
QuantiFERON-TB GOLD In-Tube - - 87.0 [76.7–93.9]
Abbreviations:
RD: region of difference; TST: tuberculin skin test; CI: confidence interval.
doi:10.1371/journal.pone.0003417.t003
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those with indeterminate results. As expected, false-negative results
to any of the immune assays considered were associated with
factors known to cause anergy such as disseminated disease.
Taken together, our results suggest that none of the tests
considered is accurate enough to be used in clinical practice to
diagnose active tuberculosis, and new approaches should be
considered. Recently, it has been shown that the discrimination of
active tuberculosis from LTBI may be ameliorated by document-
ing recruitment of M. tuberculosis-specific lymphocytes to the site of
the infection by RD1-specific ELISPOT assays [34–36] which
may open a new strategy for the distinction of the two different
status of tuberculosis.
Another recent study suggests that the combination of different
immunodiagnostic tests may improve their diagnostic accuracy
[21]. In fact it has been shown that, T-SPOT.TB or a new
ELISPOT assay incorporating the Rv3879c to RD1 antigens,
when used in combination with TST have an increased positive
and negative likelihood ratio compared with single tests suggesting
that this approach can be used to exclude active tuberculosis in
patients with moderate to high pre-test probability of disease [21].
The results of the present study confirm and extend these findings.
In fact, we confirmed the diagnostic performance of the
commercial version of T-SPOT.TB when combined to TST,
and additionally, we substantiated the data analyzing the results
obtained by the assay based on RD1 selected peptides and the
QuantiFERON-TB GOLD In-Tube. The likelihood ratio of a
negative test result that was 0.38 with the assay based on RD1
selected peptides, became 0.19 when combined with a negative
TST. Similarly, the combination of a negative result of the
QuantiFERON-TB GOLD In-Tube assay with a negative TST
scoring reached the lowest negative likelihood ratio of 0.07. This
means that while a negative result to RD1 selected peptides test
reduces 2.6-fold the odds of tuberculosis, a negative result to both
tests, RD1 selected peptides and TST, would reduce the odds of
tuberculosis 5.3-fold and using the combination of TST and
Table 4. Estimates of likelihood ratios for the combination of the diagnostic tests studied according to the disease status.
Combined tests
Subjects with
Active TB n (%)
Subjects without Active
TB n (%)
Combined likelihood
ratio [CI]
RD1 test pos/TST pos 116 (68.1) 35 (23.3) 2.92 [2.15–3.98]
RD1 test neg/TST neg 13 (7.7) 60 (40.0) 0.19 [0.11–0.33]
RD1 test pos/TST neg 11 (6.5) 12 (8.00) 0.81 [0.37–1.78]
RD1 test neg/TST pos 30 (17.7) 43 (28.7) 0.62 [0.41–0.93]
Total 170 (100.0) 150 (100.0)
RD1 test pos/QuantiFERON pos 99 (64.3) 19 (20.0) 3.21 [2.11–4.89]
RD1 test neg/ QuantiFERON neg 22 (14.3) 55 (57.8) 0.25 [0.16–0.38]
RD1 test pos/ QuantiFERON neg 12 (7.8) 3 (3.2) 2.47 [0.71–8.52]
RD1 test neg/ QuantiFERON pos 21 (13.6) 18 (19.0) 0.72 [0.40–1.28]
Total 154 (100.0) 95 (100.0)
RD1 test pos/T-SPOT.TB pos 60 (68.1) 30 (30.9) 2.20 [1.59–3.07]
RD1 test neg/T-SPOT.TB neg 10 (11.4) 41 (42.3) 0.27 [0.14–0.50]
RD1 test pos/T-SPOT.TB neg 3 (3.4) 2 (2.1) 1.65 [0.28–9.67]
RD1 test neg/T-SPOT.TB pos 15 (17.1) 24 (24.7) 0.69 [0.39–1.23]
Total 88 (100.0) 97 (100.0)
QuantiFERON pos/TST pos 81 (65.8) 23 (30.7) 2.15 [1.49–3.09]
QuantiFERON neg/TST neg 3 (2.4) 27 (36.0) 0.07 [0.02–0.22]
QuantiFERON pos/TST neg 19 (15.5) 9 (12.0) 1.29 [0.61–2.70]
QuantiFERON neg/TST pos 20 (16.3) 16 (21.3) 0.76 [0.42–1.38]
Total 123 (100.0) 75 (100.0)
QuantiFERON pos/T-SPOT.TB pos 50 (72.5) 20 (41.7) 1.74 [1.21–2.51]
QuantiFERON neg/T-SPOT.TB neg 9 (13.0) 24 (50.0) 0.26 [0.13–0.51]
QuantiFERON pos/T-SPOT.TB neg 2 (2.9) 0 (0.0) NA
QuantiFERON neg/T-SPOT.TB pos 8 (11.6) 4 (8.3) 1.39 [0.44–4.36]
Total 69 (100.0) 48 (100.0)
TST pos/T-SPOT.TB pos 50 (72.4) 29 (36.7) 1.97 [1.43–2.73]
TST neg/T-SPOT.TB neg 2 (2.9) 23 (29.1) 0.10 [0.02–0.41]
TST pos/T-SPOT.TB neg 5 (7.3) 10 (12.7) 0.57 [0.21–1.59]
TST neg/T-SPOT.TB pos 12 (17.4) 17 (21.5) 0.81 [0.42–1.57]
Total 69 (100.0) 79 (100.0)
Abbreviations:
TB: tuberculosis; RD: region of difference; RD1 test: test based on the RD1 selected peptides; TST: tuberculin skin test; CI: confidence interval; pos: positive; neg: negative;
QuantiFERON: QuantiFERON-TB GOLD In-Tube.
doi:10.1371/journal.pone.0003417.t004
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currently be the best available option to rapidly exclude
tuberculosis by immunodiagnostic tests. Conversely, a positive
result of the assay based on RD1 selected peptides with a
corresponding likelihood ratio of 2.48 is of limited value and it is
not significantly modified in those with positive results from either
the assays based on RD1 selected peptides or the TST or
QuantiFERON-TB GOLD In-Tube (likelihood ratio goes up to
2.92 and 3.21 respectively). Similarly, results on other tests
combinations improve the positive likelihood ratio of the single test
per se, but do not increase significantly that obtained by the
combination of RD1 selected peptides with TST or Quanti-
FERON-TB GOLD In-Tube.
The higher sensitivity of combined use of the novel assay or
commercial IGRAs with TST reflects the fact that patients who
had a false-negative result with one test were distinct from those
who had a false-negative result with the other. This implies that
distinct immunologic processes underlie failure of these different,
yet complementary, immune-based tests.
The study has some limitations. Not all individuals were tested
by all the assays in parallel, as not all techniques for the different
tests were established in the participating centers. In addition, the
restricted number of immunocompromised patients does not allow
a generalization of the results to this patients group. However, the
prospective and multicenter design of the study, the high
consistency of data across the different centers and the large
number of patients enrolled to evaluate the diagnostic accuracy of
different immune based tests in clinical practice render the results
robust.
In conclusion, current approaches to elicit M. tuberculosis-specific
immune responses in PBMC or in the skin by using either a broad
or narrow spectrum of epitopes of RD1 mycobacterial antigens
have a limited value for the diagnosis of active tuberculosis, as
these tests do not reliably distinguish patients with active
tuberculosis from those without. This is important to be
considered in populations with a high pre-test probability of M.
tuberculosis infection. However, the combined use of negative test
results obtained by IGRAs or the test based on RD1 selected
peptides with TST may enable rapid exclusion of tuberculosis.
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